Daré Bioscience, Inc. (DARE) Reaches $1.40 1 Year Low; Arotech Has 1.13 Sentiment

February 15, 2018 - By Adrian Erickson

The stock of Daré Bioscience, Inc. (NASDAQ:DARE) hit a new 52-week low and has $1.36 target or 3.00% below today’s $1.40 share price. The 8 months bearish chart indicates high risk for the $8.49M company. The 1-year low was reported on Feb, 15 by Barchart.com. If the $1.36 price target is reached, the company will be worth $254,610 less. The stock decreased 2.54% or $0.04 during the last trading session, reaching $1.4. About 744,119 shares traded or 185.63% up from the average. Daré Bioscience, Inc. (NASDAQ:DARE) has 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Arotech Corporation provides defense and security products worldwide. The company has market cap of $83.68 million. The companyÂ’s Training and Simulation division develops, makes, and markets multimedia and interactive digital solutions for engineering, use-of-force training, and operator training of military, law enforcement, security, emergency services, and other personnel. It currently has negative earnings. This division offers simulators, systems engineering support, and software products for training vehicle operators to the United States military, government, municipalities, and private industry; weapon simulations used to train military pilots, weapon employment information used in air launched weapons, and part-task simulators to train aircrew; specialized use-of-force training simulators and systems for police, security personnel, and the military under the MILO Range trade name; and consulting and development support services under the Realtime Technologies trade name.

Daré Bioscience, Inc. develops and commercializes product for women’s reproductive health, Ovaprene. The company has market cap of $8.49 million.

Analysts await Arotech Corporation (NASDAQ:ARTX) to report earnings on March, 21. They expect $0.08 earnings per share, up 700.00% or $0.07 from last year’s $0.01 per share. ARTX’s profit will be $2.08 million for 10.06 P/E if the $0.08 EPS becomes a reality. After $0.06 actual earnings per share reported by Arotech Corporation for the previous quarter, Wall Street now forecasts 33.33% EPS growth.

Cannell Capital Llc holds 2.18% of its portfolio in Arotech Corporation for 1.77 million shares. Essex Investment Management Co Llc owns 427,899 shares or 0.24% of their US portfolio. Moreover, Thompson Davis & Co. Inc. has 0.06% invested in the company for 7,500 shares. The Us-based Ancora Advisors Llc has invested 0.05% in the stock. Gsa Capital Partners Llp, a United Kingdom-based fund reported 173,700 shares.

The stock increased 0.78% or $0.02 during the last trading session, reaching $3.22. About 32,602 shares traded. Arotech Corporation (ARTX) has risen 16.10% since February 15, 2017 and is uptrending. It has underperformed by 0.60% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: